Carbonic anhydrase inhibition as a cancer therapy: A review of patent literature, 2007 - 2009

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 6, 2010, Pages 795-806

  Poulsen, Sally Ann ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Cancer; Carbonic anhydrase; Carbonic anhydrase inhibitor; Click chemistry; Hypoxia; Nitric oxide; Radiopharmaceutical; Sulfamate; Sulfonamide

Indexed keywords

ACETAZOLAMIDE; BRINZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; DICLOFENAMIDE; ETHOXZOLAMIDE; HYPOXIA INDUCIBLE FACTOR; MONOCLONAL ANTIBODY G250; SHORT HAIRPIN RNA; SULFONAMIDE; TOPIRAMATE;

CANCER DIAGNOSIS; CANCER THERAPY; CELL PH; CLINICAL TRIAL; COLORECTAL CANCER; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; EPILEPSY; GENE SILENCING; HUMAN; HYPOXIA; KIDNEY CANCER; MIGRAINE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CELL HYPOXIA; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; PATENTS AS TOPIC;

EID: 77952571665     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.484803     Document Type: Review

References (38)

1. Krishnamurthy VM, Kaufman GK, Urbach AR, et al. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein- ligand binding. Chem Rev 2008;108:946-1051
2. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-181
3. Brahimi-Horn MC, Pouyssegur J. HIF at a glance. J Cell Sci 2009;122:1055-1057
4. Wykoff CC,Beasley NJ,Watson PH,et al.Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000 ,60: 7075--83
5. Potter CPS, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003;89:2-7
6. Kaluz S, Kaluzova M, Liao S-Y, et al. Transcriptional control of the tumorand hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta Rev Cancer 2009;1795:162-172
7. Opavský R, Pastoreková S, Zeln?́k V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: Structure and exon to protein domain relationships. Genomics 1996;33:480-487
8. Chiche J, Ilc K, Laferrière J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009;69:358-368
9. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007;26:299-310
10. Martinez-Zaguilan R, Seftor EA, Seftor RE, et al. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996;14:176-186
11. Swietach P, Wigfield S, Cobden P, et al. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem 2008;283:20473-20483
12. Swietach P, Patiar S, Supuran CT, et al. The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in three-dimensional tumor cell growths. J Biol Chem 2009;284:20299-20310
13. Svastova E, Hulikova A, Rafajova M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577:439-445
14. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998;4:2729-2739
15. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000;85:865-870
16. Lopez M, Bornaghi LF, Innocenti A, et al. Sulfonamide linked neoglycoconjugates -- a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem 2010;53:2913-2926
17. Lopez M, Paul B, Hofmann A, et al. S-glycosyl primary sulfonamides -- A new structural class for selective inhibition of cancer-associated carbonic anhydrases. J Med Chem 2009;52:6421-6432
18. Supuran C, Scozzafava A, Pastorekova S, Pastorek J. Sulfonamide carbonic anhydrase IX-specific inhibitors for the treatment of preneoplastic and neoplastic diseases. WO048544; 2004
19. Winum J-Y, Poulsen S-A, Supuran CT. Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev 2009;29:419-435
20. Winum J-Y, Rami M, Scozzafava A, et al. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev 2008;28:445-463
21. Stiti M, Cecchi A, Rami M, et al. Carbonic anhydrase inhibitor coated gold nanoparticles selectively inhibit the tumor-associated isoform IX over the cytosolic isozymes I and II. J Am Chem Soc 2008;130:16130-16131
22. Nicox SA. Nitrate esters of carbonic anhydrase inhibitors. WO071421; 2008
23. Solvay Pharmaceuticals GMBH. Novel sulfamate compounds for medical use. WO050252; 2009
24. Maryanoff BE. Pharmaceutical "gold" from neurostabilizing agents: Topiramate and successor molecules. J Med Chem 2009;52:3431-3440
25. Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13:841-845
26. Winum J-Y, Scozzafava A, Montero J-L, Supuran CT. Sulfamates and their therapeutic potential. Med Res Rev 2005;25:186-228
27. Okada M, Iwashita S, Koizumi N. Efficient general method for sulfamoylation of a hydroxyl group. Tetrahedron Lett 2000;41:7047-7051
28. Biotechnologijos Institutas. Benzimidazo [1,2,-c][1,2,3]thiadiazol-7- sulfonamides as CA inhibitors. WO016288; 2008
29. Dudutiene V, Baranauskiene L, Matulis D. Benzimidazo[1,2-c][1,2,3] thiadiazole-7-sulfonamides as inhibitors of carbonic anhydrase. Bioorg Med Chem Lett 2007;17:3335-3338
30. Siemens Medical Solutions USA, Inc. The development of molecular imaging probes for carbonic anhydrase-IX using click chemistry. WO124703; 2008
31. Scozzafava A, Menabuoni L, Mincione L, et al. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: Is the tail more important than the ring? J Med Chem 1999:42:2641-2650 (Pubitemid 29344304)
32. Wilkinson BL, Bornaghi LF, Houston TA, et al. A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem 2006;49:6539-6548
33. Poulsen S-A, Bornaghi LF. Fragment-based drug discovery of carbonic anhydrase II inhibitors by dynamic combinatorial chemistry utilising alkene cross metathesis. Bioorg Med Chem 2006;14:3275-3284
34. Supuran CT, Scozzafava A, Conway J. Carbonic Anhydrase: Its Inhibitors and Activators. CRC Press, Florida; 2004
35. Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX. WO089383; 2009
36. Druker BJ. Perspectives on the development of imatinib and the future of cancer research. Nat Med 2009;15:1149-1152
37. Hughes B. 2009 FDA drug approvals. Nat Rev Drug Discov 2010;9:89-92
38. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006;2:689-700